Texas Retina Associates Led the Way at the 2024 VisionWalk to Benefit the Foundation Fighting Blindness
This past Saturday, Texas Retina Associates sponsored and participated in the 2024 Dallas-Fort Worth VisionWalk to benefit the Foundation Fighting Blindness and was recognized as the “Largest Team.” Our “Walk Stars” came
read more
Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more
Texas Retina Associates Led the Way at the 2023 VisionWalk to Benefit the Foundation Fighting Blindness
This past Saturday, Texas Retina Associates sponsored and participated in the 2023 Dallas-Fort Worth VisionWalk to benefit the Foundation Fighting Blindness and was recognized as the “Largest Team.” Our “Walk Stars” came
read more
Four New Clinical Trials Available at Texas Retina Associates
Our physicians remain committed to participating in ongoing retina research and providing our patients access to promising new treatment options through clinical trials. We recently opened four new clinical trials: Diabetic Macular
read more
Texas Retina Associates Celebrates Employees Who Have Contributed 25+ Years of Service
As a new year begins, we would like to take a moment to thank and congratulate 12 employees who have served Texas Retina Associates for 25 or more years: Laurie A. Griffis,
read more
Texas Retina Associates Announces the Retirement of Rand Spencer, MD
It is with bittersweet emotion that we announce the retirement of Rand Spencer, MD, from Texas Retina Associates effective December 31, 2022. He has been caring for patients at our practice since
read more
Texas Retina Associates’ New Waco Area Office Opening September 27!
We’re excited to announce that our new, larger Waco area office will officially open on September 27, 2022! Allowing us to better serve patients in this rapidly growing community, this new office
read more
Texas Retina Associates First in the Country to Dose a Patient in the DAVIO 2 Clinical Trial
Texas Retina Associates is honored to have randomized the first patient in EyePoint Pharmaceuticals’ Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901 for patients with wet macular
read more
Texas Retina Associates Announces the Retirement of David Callanan, MD
It is with mixed emotions that we announce the retirement of David Callanan, MD, from Texas Retina Associates effective June 30, 2022. He has been caring for patients at our practice since
read more
Texas Retina Associates Now Offers Online Appointment Requests!
We are committed to continuing to look for new ways to enhance accessibility and convenience for our patients. That is why we’re excited to share that you can now request an appointment
read more